CRPA1A2

N/A

Report date: 2026/05/20 20:02:01

Base Information

Drug NameCRPA1A2
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionMelanoma-associated antigen 1 modulatorsT lymphocyte replacements
TargetsMelanoma-associated antigen 1
Therapy Area/IndicationsSolid tumoursLung NeoplasmsHead and Neck Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesCorregene Biotechnology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesCorregene Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursLung NeoplasmsHead and Neck Neoplasms +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A